A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 975
- Population
- ALL · 50 Years to 85 Years
- Duration
- 2024-10-30 to 2033-04-09
- Intervention
- Pozelimab; Cemdisiran; Placebo
- Comparator
- Placebo treatment group
- Outcomes measured
- Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF) — To…; Loss of Best Corrected Visual Acuity (BCVA) ≥15 letters [Early Treatment Diabetic Retinopathy Study (ETDRS)] from basel…; Change from baseline in Low-Contrast quantitative Visual Acuity (LC-qVA) — At week 52 and week 104; Change from baseline in Low-Luminance Low-Contrast quantitative Visual Acuity (LL-LC-qVA) — At week 52 and week 104; Change from baseline in quantitative Contrast Sensitivity Function (qCSF) — At week 52 and week 104; Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline measured by FAF — To week 104; Concentrations of total pozelimab in serum — Through week 52 and through week 104; Concentrations of total cemdisiran in plasma — Through week 52 and through week 104; Change from baseline in concentration of total Complement component 5 (C5) — Through week 52 and through week 104; Incidence of Antidrug antibody (ADA) to pozelimab — Through week 52 and through week 104; Magnitude of ADA to pozelimab — Through week 52 and through week 104; Incidence of ADA to cemdisiran — Through week 52 and through week 104; Magnitude of ADA to cemdisiran — Through week 52 and through week 104; Incidence of Neutralizing Antibody (NAb) to pozelimab — Through week 52 and through week 104; Occurrence of Treatment-Emergent Adverse Events (TEAEs) — Through week 52, 104, 140 and week 296; Severity of TEAEs — Through week 52, 104, 140 and week 296
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.